A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer
Open Access
- 15 May 2004
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (10) , 3365-3370
- https://doi.org/10.1158/1078-0432.ccr-03-0404
Abstract
Purpose: To assess the activity of the antiangiogenic agent and VEGFR2 inhibitor SU5416 in hormone-refractory prostate cancer.Keywords
This publication has 16 references indexed in Scilit:
- Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate CancerJournal of Urology, 2002
- Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid TumorsJournal of Clinical Oncology, 2002
- Vascular Endothelial Growth Factor: Acting as an Autocrine Growth Factor for Human Gastric Adenocarcinoma Cell MGC803Biochemical and Biophysical Research Communications, 2001
- Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Flk-1 in Benign, Premalignant, and Malignant Prostate TissueAmerican Journal of Clinical Pathology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancerUrology, 1999
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblastsOncogene, 1997
- Serum basic fibroblast growth factor in men with and without prostate carcinomaCancer, 1995
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986